| Document and Entity Information (USD $) | 3 Months Ended | |
| Mar. 31, 2014 | 12-May-14 | |
| Document and Entity Information: | ' | ' |
| Entity Registrant Name | 'PROTECT PHARMACEUTICAL Corp | ' |
| Document Type | '10-Q | ' |
| Document Period End Date | 31-Mar-14 | ' |
| Amendment Flag | 'false | ' |
| Entity Central Index Key | '0001493526 | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Entity Common Stock, Shares Outstanding | ' | 44,573,012 |
| Entity Public Float | ' | $44,573,012 |
| Entity Filer Category | 'Smaller Reporting Company | ' |
| Entity Current Reporting Status | 'No | ' |
| Entity Voluntary Filers | 'No | ' |
| Entity Well-known Seasoned Issuer | 'No | ' |
| Document Fiscal Year Focus | '2014 | ' |
| Document Fiscal Period Focus | 'Q1 | ' |
| Condensed Balance Sheets (USD $) | 320 Months Ended | |
| Mar. 31, 2014 | Dec. 31, 2013 | |
| ASSETS | ' | ' |
| Cash | $636 | $681 |
| Total Current Assets | 636 | 681 |
| TOTAL ASSETS | 636 | 681 |
| Accounts payable and accrued expenses | 60,104 | 60,104 |
| Accounts payable - related parties | 24,434 | 23,939 |
| Notes payable - related parties | 24,940 | 24,940 |
| Other accrued expenses | 486,826 | ' |
| Total Current Liabilities | 596,304 | 595,809 |
| TOTAL LIABILITIES | 596,304 | 595,809 |
| Common stock; 100,000,000 shares authorized, at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively | 222,865 | 222,865 |
| Additional paid-in capital | 8,356,480 | 8,354,980 |
| Deficit accumulated during the development stage | -9,175,013 | -9,172,973 |
| Total Stockholders' Deficit | -595,668 | -595,128 |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $636 | $681 |
| Condensed Statements of Operations (USD $) | 3 Months Ended | 320 Months Ended | |
| Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | |
| REVENUES | ' | ' | ' |
| Research and development | ' | ' | $1,353,540 |
| Professional Fees | 495 | 1,586 | 1,499,238 |
| Executive compensation | 1,500 | 1,500 | 5,896,230 |
| General and administrative | 45 | 44 | 447,164 |
| LOSS FROM OPERATIONS | -2,040 | -3,130 | -9,196,172 |
| Proceeds from sale of patents | ' | ' | 640,000 |
| LOSS BEFORE DISCONTINUED OPERATIONS | -2,040 | -3,130 | -8,556,172 |
| LOSS FROM DISCONTINUED OPERATIONS | ' | ' | -4,340,551 |
| PROFIT (LOSS) | ($2,040) | ($3,130) | ($12,896,723) |
| BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK | $0 | $0 | ' |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 44,573,012 | 44,573,012 | ' |
| Condensed Statements of Cash Flows (USD $) | 3 Months Ended | 320 Months Ended | |
| Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | |
| OPERATING ACTIVITIES | ' | ' | ' |
| Net loss | ($2,040) | ($3,130) | ($12,896,723) |
| Services contributed by an officer | 1,500 | 1,500 | 13,500 |
| Common stock issued for services | ' | ' | 9,904,653 |
| Common stock issued for research and development costs | ' | ' | 1,250,000 |
| Loss from disposition of subsidiary | ' | ' | 564,300 |
| Expenses paid on behalf of the Company | ' | 1,000 | 90,459 |
| Gain on sale of patent | ' | ' | -640,000 |
| Accounts payable | ' | ' | 60,105 |
| Change in Account payable - related parties | 495 | 586 | 168,196 |
| Prepaid expenses | 491,667 | ' | 491,667 |
| Other accrued expenses | ' | ' | 486,826 |
| Net Cash Provided by (Used in) Operating Activities | -45 | -44 | -507,017 |
| Proceeds from sale of patent | ' | ' | 640,000 |
| Net Cash Used in Investing Activities | ' | ' | 640,000 |
| Capital contributed by officer | ' | ' | 13,046 |
| Proceeds from related party payable | ' | ' | 100 |
| Repayment of related party payable | ' | ' | -145,493 |
| Net Cash Provided by (Used in) Financing Activities | ' | ' | -132,347 |
| NET INCREASE (DECREASE) IN CASH | -45 | -44 | 636 |
| CASH AT BEGINNING OF PERIOD | 681 | 860 | ' |
| CASH AT END OF PERIOD | 636 | 816 | 636 |
| Common stock issued for prepaid services | ' | ' | $750,000 |
| Note 1 - Condensed Financial Statements | 3 Months Ended |
| Mar. 31, 2014 | |
| Notes | ' |
| Note 1 - Condensed Financial Statements | ' |
| NOTE 1 - CONDENSED FINANCIAL STATEMENTS | |
| The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at March 31, 2014, and for all periods presented herein, have been made. | |
| Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended March 31, 2014 and 2013 are not necessarily indicative of the operating results for the full years. | |
| Note 2 - Going Concern | 3 Months Ended |
| Mar. 31, 2014 | |
| Notes | ' |
| Note 2 - Going Concern | ' |
| NOTE 2 - GOING CONCERN | |
| The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company the Company had accumulated losses of $9,175,013 for the period from inception through March 31, 2014 which raises substantial doubt about its ability to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses. |
| Note 3 - Significant Accounting Policies | 3 Months Ended |
| Mar. 31, 2014 | |
| Notes | ' |
| Note 3 - Significant Accounting Policies | ' |
| NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES | |
| Use of Estimates | |
| The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
| Basic (Loss) per Common Share | |
| Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of March 31, 2014 and 2013. | |
| Recent Accounting Pronouncements | |
| The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements. |
| Note 4 - Accounts Payable-related Party | 3 Months Ended |
| Mar. 31, 2014 | |
| Notes | ' |
| Note 4 - Accounts Payable-related Party | ' |
| NOTE 4 – ACCOUNTS PAYABLE-RELATED PARTY | |
| The Company owed trade accounts payable to a related party in the amount of $24,434, and $23,939, as of March 31, 2014, and December 31, 2013, respectively. | |
| Note 6 - Sale of Patents | 3 Months Ended |
| Mar. 31, 2014 | |
| Notes | ' |
| Note 6 - Sale of Patents | ' |
| NOTE 6 – SALE OF PATENTS | |
| On January 31, 2011, Protect Pharmaceutical Corporation (the “Company”) finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain. | |
| In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance will be paid to Nectid. The Company retains all | |
| other inventions, patents and technologies initially acquired from Nectid. | |
| Note 3 - Significant Accounting Policies: Use of Estimates (Policies) | 3 Months Ended |
| Mar. 31, 2014 | |
| Policies | ' |
| Use of Estimates | ' |
| Use of Estimates | |
| The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
| Note 3 - Significant Accounting Policies: Basic (loss) Per Common Share (Policies) | 3 Months Ended |
| Mar. 31, 2014 | |
| Policies | ' |
| Basic (loss) Per Common Share | ' |
| Basic (Loss) per Common Share | |
| Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of March 31, 2014 and 2013. |
| Note 3 - Significant Accounting Policies: Recent Accounting Pronouncements (Policies) | 3 Months Ended |
| Mar. 31, 2014 | |
| Policies | ' |
| Recent Accounting Pronouncements | ' |
| Recent Accounting Pronouncements | |
| The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements. |
| Note 5 - Related Party Transactions (Policies) | 3 Months Ended |
| Mar. 31, 2014 | |
| Policies | ' |
| Note 5 - Related Party Transactions | ' |
| NOTE 5 – RELATED PARTY TRANSACTIONS | |
| The Company has recorded advances from related parties and expenses paid by related parties on behalf of the Company as related party payables. As of March 31, 2014 and December 31, 2013, the related party payable outstanding balance totaled $24,940 and $24,940, respectively. These payables are non-interest bearing, unsecured, and are due on demand. | |
